Therefore, FAK inhibition promotes greater responsiveness to the anti-tumor effects of T-cell co-stimulation through reprogramming multiple immune regulatory pathways, supporting further development of these combinations for clinical testing. This evidence concerns the gene PTK2 and neoplasm.